Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the down-regulated miRNAs in SCI, 21, 19 and 20 miRNAs were potentially associated with hematological, bladder and esophageal cancer, respectively, and three target genes (<i>TP53, CCND1 and KRAS</i>) were common to all three types of cancer.
|
31444279 |
2019 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of plasma miR-93-5p expression significantly increases the risk of esophageal cancer and is associated with poor prognosis. miR-93-5p transferred by exosomes promotes the proliferation of recipient esophageal cancer cells and affects the expression of PTEN and its downstream proteins p21 and cyclin D1.
|
29673440 |
2018 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pin1 is a critical therapeutic and preventive target in esophageal cancer because of its positive regulation of β-catenin and cyclin D1.
|
28325828 |
2017 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the molecular functions of cyclin D1 on EMT phenotypes and esophageal cancer radiosensitivity, we treated the radioresistant esophageal cancer cells (KYSE-150R) and parental cells (KYSE-150) with cyclin D1 small interfering RNA (siRNA).
|
26561473 |
2016 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PAR-2 regulate cell proliferation through the MAPK pathway in esophageal carcinoma cell, and Cyclin D1, c-fos are involved in this process.
|
27906434 |
2016 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We utilized a murine esophageal cancer cell line established from the ED-L2-cyclin D1;p53 mouse that was transduced to express a viral tumor antigen, the Human Papilloma Virus (HPV) E7 protein.
|
24810640 |
2014 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, S6 and S6 kinase 1 knockdown resulted in attenuation of viability by suppressing cyclin D1 expression in esophageal cancer cells.
|
22996377 |
2013 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our results suggest that the CCND1 G870A polymorphism might not be a potential candidate for predicting esophageal cancer risk.
|
23661400 |
2013 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggested that CCND1 amplification and co-alternation of CCND1(+) /pRb(-) /ppRb(+) may play a crucial role in the prognostic evaluation of patients with esophageal cancer, and the patients with CCND1(+) /pRb(-) /ppRb(+) have the worst prognosis in all the patients.
|
22150974 |
2013 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Collectively, results suggest that CCND1 G870A polymorphism might be a low-penetrant risk factor for esophageal carcinoma, particularly among Asians.
|
23020291 |
2012 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling.
|
21785828 |
2011 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In CCND1 G870A polymorphism, the AA genotype was marginally associated with higher risk of esophageal cancer (OR 1.5, 95%CI=0.98-2.4, P=0.05).
|
17561354 |
2007 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer.
|
16732330 |
2006 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 overexpression in esophageal cancer from southern China and its clinical significance.
|
16051426 |
2006 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCND1 gene amplification (45%) was more prevalent than polysomy (25%) in esophageal carcinoma, but the pattern observed was similar in gastric adenocarcinoma (10% amplification, 15% polysomy).
|
16490596 |
2006 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Egr-1, c-fos and cyclin D1 varies in esophageal precancerous lesions and cancer tissues, suggesting an involvement of these genes in the development of esophageal carcinoma.
|
14966901 |
2004 |
Esophageal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CCND1-EMS1 locus on human chromosome 11q13 is amplified in esophageal cancer, bladder tumors, and breast cancer.
|
12739008 |
2003 |
Esophageal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased DNA content and heteroploid rate, accumulation of p53 protein, and over-expression of p21, telomerase and cyclin D1 proteins were early molecular events during the development of esophageal cancer.
|
14606066 |
2003 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the possible role of cyclin D1 overexpression on specific malignant properties of tumor cells using a series of eight human esophageal cancer cell lines that express different levels of cyclin D1.
|
12014632 |
2002 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 and MDM-2 amplification and cyclin D1 overexpression occur, although infrequently, in the development of oesophageal carcinoma.
|
10419705 |
1999 |
Esophageal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Amplification of the cyclin D1 gene is a reliable prognostic factor and post-translational modification of this gene may play a functionally important role in development of primary esophageal cancer.
|
9458316 |
1998 |
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To further address the roles of cyclin D1 in growth control and tumorigenesis, we have overexpressed an antisense cyclin D1 cDNA construct, either constitutively or inducibly, in the HCE7 human esophageal cancer cell line in which cyclin D1 is amplified and expressed at high levels.
|
7630641 |
1995 |